A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: marks (231), results (1000)

Daratumumab SC Ver1

Description
Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

HSCTMelphalan-Bortezomib IV

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT AUTOGRAFT InP - MELPHALAN and BORTEZOMIB (IV) Please confirm correct protocol with transplant schedule Regimen • HSCT – InP - Melphalan
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTMelphalan-Bortezomib-IV.pdf

Niraparib

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCERS Regimen NIRAPARIB • Ovarian Cancer – Niraparib Indication • Niraparib is recommended as maintenance treatment in patients with relapsed, platinum
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Niraparib.pdf

SHAPE Award Guide

Description
SHAPE FUNDING AWARDS Southampton Academy of Research (SoAR) in collaboration with Applied Research Collaboration (ARC Wessex) 1. Internship Awards 2. Transitional
Url
/Media/Southampton-Clinical-Research/Downloads/SHAPE-Award-Guide.pdf

2025 WRES report and action plan

Description
Workforce Race Equality Standard Annual Report 2025 1 Executive Summary WRES Data has been submitted by the Trust
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/2025-wres-report-and-action-plan.pdf

Tisacel -Cyclophosphamide (250)-Fludarabine (25)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – FLUDARABINE (25) – CYCLOPHOSPHAMIDE (250) Regimen This regimen will
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Cyclophosphamide-250-Fludarabine-25.pdf

Endometrial Carboplatin-Cisplatin-PaclitaxelRT(21day)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-CISPLATIN-PACLITAXEL RT Regimen • Endometrial-Carboplatin (AUC5)-Cisplatin-Paclitaxel RT Indication • The treatment of endometrial
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Endometrial-Carboplatin-Cisplatin-Paclitaxel-RT-21day.pdf

Inotuzumab Ozogamicin

Description
Relapsed or refractory CD22-positive B-Cell acute lymphoblastic leukaemia.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Inotuzumab-Ozogamicin.pdf

Gefitinib

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) GEFITINIB Regimen NSCLC - Gefitinib Indication Gefitinib is recommended as an option for the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Gefitinibver13.pdf

RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab

Description
Chemotherapy Protocol LYMPHOMA CISPLATIN-DEXAMETHASONE-GEMCITABINE-RITUXIMAB (RGDP) Regimen • Lymphoma – RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab Indication • Patients with relapsed aggressive B
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab.pdf
351 to 360 of 548
Previous … 34 35 36 37 38 … Next